论文部分内容阅读
目的:探讨布地奈德雾化吸入治疗呼吸道合胞病毒、鼻病毒感染所致婴幼儿喘息第一次发作时的疗效。方法:2004年5月～2006年5月因第一次轻中度喘息发作在苏州大学附属儿童医院哮喘中心住院治疗的患儿212例,入院后随机分成治疗组与对照组,对照组采用空气压缩泵吸入万托林雾化液;治疗组在吸入万托林雾化液的基础上吸入布地奈德悬液。采用直接免疫法检测新鲜痰液标本中的呼吸道合胞病毒(RSV)、腺病毒(ADV)、流感病毒(IFV)和副流感病毒(PIV);用RT-PCR法检测标本中的鼻病毒(RV)基因。采用UniCAP荧光酶系统进行过敏原过筛试验。收集患儿的出生史及特异性疾病的家族史。比较治疗组与对照组中单纯感染RSV或RV患儿的平均住院时间;同时比较单纯RSV感染患儿与单纯RV感染患儿的平均住院时间;比较治疗组中RV感染患儿与对照组中RV感染患儿的平均住院时间;比较治疗组中RSV感染患儿与对照组中RSV感染患儿的平均住院时间。结果:①治疗组单纯感染RSV或RV患儿平均住院时间为(6.71±1.79)天,对照组单纯感染RSV或RV患儿平均住院时间为(7.25±1.64)天,两组相比差异无统计学意义(P>0.05)。②RSV感染患儿平均住院时间为(7.25±1.86)天,RV感染患儿平均住院时间为(6.64±1.54)天,两组相比差异无统计学意义(P>0.05)。③治疗组RV患儿平均住院时间为(6.01±1.03)天,与对照组RV患儿平均住院时间〔(7.5±1.73)天〕相比,差异有统计学意义(P<0.05)。④治疗组RSV患儿平均住院时间为(7.46±2.13)天,与对照组RSV患儿平均住院时间〔(7.06±1.61)天〕相比,差异无统计学意义(P>0.05)。结论:布地奈德吸入治疗能缩短RV喘息患儿的平均住院时间,但对RSV喘息患儿的住院时间无影响。
OBJECTIVE: To investigate the efficacy of inhaled budesonide in the treatment of respiratory syncytial virus (RSV) and infantile wheeze caused by rhinovirus infection in the first attack. Methods: From May 2004 to May 2006, 212 children hospitalized for asthma in the Children’s Hospital Affiliated to Soochow University were treated with mild to moderate wheezing. After admission, they were randomly divided into treatment group and control group. The control group received air Compression pump inhaled Wantropin atomized solution; the treatment group inhaled budesonide suspension on the basis of inhalation of vaterol. The respiratory syncytial virus (RSV), adenovirus (ADV), influenza virus (IFV) and parainfluenza virus (PIV) in fresh sputum were detected by direct immunosorbent assay. The rhinovirus RV) gene. UniCAP luciferase system for allergen screening test. Collect family history of birth and specific illness in children. The mean length of stay in children with RSV or RV alone was compared between the treatment group and the control group. The mean length of stay was also compared between children with RSV infection and those with RV infection alone. The RV The average length of hospital stay in infants infected with RSV was compared with that in infants with RSV infection in the treatment group and in the control group. Results: ① The average length of hospital stay (RSD) or RV in the treatment group was (6.71 ± 1.79) days, while that in the control group with RSV or RV alone was (7.25 ± 1.64) days. There was no statistical difference between the two groups Significance (P> 0.05). ② The average length of hospital stay of children with RSV infection was (7.25 ± 1.86) days, and the average length of hospital stay was (6.64 ± 1.54) days in children with RV infection. There was no significant difference between the two groups (P> 0.05). ③ The mean length of stay in children with RV was (6.01 ± 1.03) days in the treatment group, which was significantly different from that in the control group (7.5 ± 1.73 days) 〔(7.5 ± 1.73) days〕 (P0.05. ④ The average length of hospital stay of RSV children in the treatment group was (7.46 ± 2.13) days, which was not significantly different from that of the control children in RSV 〔(7.06 ± 1.61) days〕 〔(P> 0.05). Conclusion: Budesonide inhalation therapy can shorten the average hospital stay in children with RV wheeze, but has no effect on the length of hospital stay in children with RSV wheeze.